A Phase 1, Open-Label Study to Compare the Relative Bioavailability of Two AG-881 Formulations and to Evaluate the Effect of Food and Multiple-Dose Omeprazole on the Pharmacokinetics of a Single Dose of AG-881 in Healthy Adult Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Vorasidenib (Primary) ; Omeprazole
- Indications Glioma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Agios Pharmaceuticals
- 11 Feb 2020 Status changed from active, no longer recruiting to completed.
- 03 Dec 2019 Planned End Date changed from 18 Dec 2019 to 11 Dec 2019.
- 03 Dec 2019 Planned primary completion date changed from 18 Dec 2019 to 11 Dec 2019.